New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.

Autor:	Simon N; Department of Oncology, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 12C432B, Bethesda, MD 20892, USA., Atiq S; Department of Oncology, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10 - Magnuson Clinical Center, Room B2L312, Bethesda, MD, 20892, USA., Sonpavde G; Department of Urology, AdventHealth Cancer Institute, University of Central Florida, 2501 North Orange Avenue, Orlando, FL 32804, USA., Apolo A; Department of Oncology, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10 - Magnuson Clinical Center, Room 13N240, Bethesda, MD 20892, USA. Electronic address: andrea.apolo@nih.gov.
Jazyk:	angličtina
Zdroj:	The Urologic clinics of North America [Urol Clin North Am] 2024 Aug; Vol. 51 (3), pp. 367-376. Date of Electronic Publication: 2024 May 18.
DOI:	10.1016/j.ucl.2024.03.005
Abstrakt:	Penile cancer is a rare malignancy with a poor prognosis. Studies with single-agent immune checkpoint inhibitors (ICIs) have demonstrated efficacy, but response rates are low. Studies combining ICIs with both chemotherapy and targeted therapy are ongoing. Up to 50% of penile cancer cases are associated with human papillomavirus (HPV). HPV-targeting therapies, such as HPV-targeting vaccines and T-cell receptor therapies, are an area of active investigation. Penile cancer cells also express cell surface antigens that may be targeted by the emerging class of antibody-drug conjugates. Competing Interests: Disclosure Nicholas Simon, Saad Atiq, and Andrea Apolo report no disclosures. Guru Sonpavde reports the following disclosures: Advisory Board: EMD Serono, BMS, Merck, Seattle Genetics/Astellas, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, Eli Lilly/Loxo Oncology, Vial, PrecisCa, Atkis, Kura Oncology, Daiichi-Sankyo.Consultant/Scientific Advisory Board (SAB): Syapse, Merck, Servier, Syncorp.Research Support to institution: EMD Serono, Jazz Therapeutics, BMS.Speaker: Seagen, Gilead, Natera, Exelixis, Janssen, Astellas, Bayer, Aveo, Merck, Pfizer.CME-certified speaking: Research to Practice, PeerView Institute, Ideology Health, IBCU/Grand Rounds in Urology.Data safety monitoring committee (honorarium): Mereo. Employment: Spouse employed by Myriad. Writing/Editor fees: Uptodate, Practice Update, Onviv, DAVA Oncology. Travel: BMS, Astellas. (Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu